MCID: PNC129
MIFTS: 65

Pancreatic Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pancreatic Adenocarcinoma

MalaCards integrated aliases for Pancreatic Adenocarcinoma:

Name: Pancreatic Adenocarcinoma 11 28 5 14 16 33
Adenocarcinoma of Pancreas 71 33
Mixed Adenocarcinoma Islet Cell with Exocrine of Unspecified Site 33
Islet Cell Adenocarcinoma of Unspecified Site 33
Adenocarcinoma of Islet Cell of Pancreas 33
Primary Pancreatic Adenocarcinoma 33
Adenocarcinoma of the Pancreas 11
Malignant Exocrine Neoplasm 33
Pancreas Adenocarcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:4074
NCIt 49 C8294
SNOMED-CT 68 700423003
ICD11 33 1663659989
UMLS 71 C0281361

Summaries for Pancreatic Adenocarcinoma

Disease Ontology: 11 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Pancreatic Adenocarcinoma, also known as adenocarcinoma of pancreas, is related to pancreatic ductal adenocarcinoma and adenocarcinoma, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Adenocarcinoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Propofol and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include pancreas, t cells and lymph node, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Related Diseases for Pancreatic Adenocarcinoma

Diseases related to Pancreatic Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 873)
# Related Disease Score Top Affiliating Genes
1 pancreatic ductal adenocarcinoma 32.5 U2AF1 TP53 SMAD4 KRAS HRAS
2 adenocarcinoma 32.3 TP53 SMAD4 PIK3CA MUC4 KRAS HRAS
3 pancreatic acinar cell adenocarcinoma 32.2 SMAD4 KRAS HRAS
4 pancreatic cancer 31.6 TP53 SMAD4 PIK3CA MUC4 MAP2K2 KRAS
5 exanthem 31.2 KRAS HRAS ERBB2 EGFR
6 inherited cancer-predisposing syndrome 31.0 TP53 SMAD4 POLE EGFR CDKN2A
7 bap1 tumor predisposition syndrome 31.0 TP53 SMAD4 POLE EGFR CDKN2A
8 papilloma 31.0 TP53 KRAS ERBB2 EGFR CDKN2A
9 breast ductal carcinoma 30.9 TP53 SMAD4 ERBB2 EGFR CTNNB1
10 ampulla of vater adenocarcinoma 30.9 SMAD4 KRAS HRAS
11 cholecystitis 30.8 TP53 MUC4 EGFR CDKN2A
12 appendix adenocarcinoma 30.8 TP53 SMAD4 KRAS HRAS GNAS
13 cholangiocarcinoma 30.8 TP53 SMAD4 PIK3CA MUC4 KRAS ERBB2
14 biliary tract cancer 30.7 TP53 SMAD4 MUC4 ERBB2 EGFR
15 pancreatic ductal carcinoma 30.7 TP53 SMAD4 KRAS HRAS ERBB2 EGFR
16 pancreatoblastoma 30.7 SMAD4 KRAS HRAS CTNNB1 CDKN2A
17 peutz-jeghers syndrome 30.6 TP53 SMAD4 GNAS EGFR CTNNB1
18 cervical adenocarcinoma 30.6 TP53 KRAS CDKN2A
19 adenosquamous carcinoma 30.5 MUC4 KRAS HRAS EGFR
20 neurofibromatosis 30.5 TP53 KRAS HRAS EGFR CDKN2A
21 klatskin's tumor 30.5 TP53 KRAS HRAS
22 gastroesophageal junction adenocarcinoma 30.5 TP53 ERBB2 EGFR
23 gastric cancer 30.4 TP53 SMAD4 PIK3CA MUC4 KRAS ERBB2
24 hemangioma 30.4 TP53 KRAS EGFR CTNNB1 CDKN2A
25 adenocarcinoma in situ 30.4 U2AF1 TP53 KRAS HRAS EGFR CDKN2A
26 ampulla of vater cancer 30.4 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
27 laryngeal squamous cell carcinoma 30.4 TP53 ERBB2 EGFR CDKN2A
28 pseudomyxoma peritonei 30.3 TP53 KRAS GNAS CTNNB1
29 low grade glioma 30.3 TP53 EGFR CDKN2A
30 hereditary breast ovarian cancer syndrome 30.3 TP53 SMAD4 POLE PIK3CA KRAS HRAS
31 vaginal cancer 30.3 TP53 HRAS EGFR CDKN2A
32 duodenum adenocarcinoma 30.3 SMAD4 KRAS HRAS
33 duodenum cancer 30.3 TP53 SMAD4 KRAS HRAS ERBB2
34 diffuse gastric cancer 30.3 TP53 SMAD4 PIK3CA KRAS ERBB2 CTNNB1
35 cervical squamous cell carcinoma 30.3 TP53 SMAD4 PIK3CA KRAS EGFR CDKN2A
36 papillary adenocarcinoma 30.3 TP53 KRAS HRAS ERBB2
37 signet ring cell adenocarcinoma 30.3 TP53 KRAS HRAS ERBB2 CTNNB1
38 mucinous cystadenocarcinoma 30.3 SMAD4 KRAS HRAS
39 keratosis, seborrheic 30.3 TP53 PIK3CA CDKN2A
40 familial adenomatous polyposis 30.3 TP53 SMAD4 KRAS HRAS CTNNB1
41 brain glioma 30.2 U2AF1 TP53 ERBB2 EGFR CDKN2A
42 gallbladder disease 30.2 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
43 esophagus adenocarcinoma 30.2 TP53 ERBB2 EGFR CTNNB1 CDKN2A
44 colonic benign neoplasm 30.2 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
45 mantle cell lymphoma 30.2 U2AF1 TP53 ERBB2 EGFR CDKN2A
46 rectum cancer 30.2 TP53 KRAS HRAS EGFR
47 malignant pleural mesothelioma 30.2 TP53 HRAS EGFR CDKN2A
48 teratoma 30.2 TP53 KRAS ERBB2 CTNNB1 CDKN2A
49 barrett esophagus 30.2 TP53 SMAD4 ERBB2 CTNNB1 CDKN2A
50 suppressor of tumorigenicity 3 30.2 TP53 CDKN2A

Graphical network of the top 20 diseases related to Pancreatic Adenocarcinoma:



Diseases related to Pancreatic Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Adenocarcinoma

UMLS symptoms related to Pancreatic Adenocarcinoma:


abdominal pain; pruritus; icterus

GenomeRNAi Phenotypes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show top 50) (show all 55)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.74 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.74 EGFR HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.74 KRAS
4 Decreased viability GR00106-A-0 10.74 KRAS
5 Decreased viability GR00221-A-1 10.74 EGFR HRAS KRAS PIK3CA CDKN2A RXRA
6 Decreased viability GR00221-A-2 10.74 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.74 HRAS CDKN2A
8 Decreased viability GR00221-A-4 10.74 EGFR PIK3CA CDKN2A
9 Decreased viability GR00249-S 10.74 RXRA
10 Decreased viability GR00301-A 10.74 KRAS
11 Decreased viability GR00381-A-1 10.74 KRAS RXRA
12 Decreased viability GR00402-S-2 10.74 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10.55 MED12
14 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.55 MED12
15 Increased shRNA abundance (Z-score > 2) GR00366-A-109 10.55 MYCN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.55 MED12
17 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.55 TP53
18 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.55 TP53 KRAS U2AF1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.55 EGFR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.55 TP53
21 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.55 U2AF1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.55 MYCN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10.55 MED12 U2AF1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-165 10.55 MYCN
25 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.55 TP53
26 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.55 MYCN
27 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.55 MYCN
28 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.55 TP53
29 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.55 MED12
30 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.55 TP53
31 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.55 MED12 TP53
32 Increased shRNA abundance (Z-score > 2) GR00366-A-20 10.55 TP53
33 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.55 EGFR
34 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.55 U2AF1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.55 EGFR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.55 KRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.55 MED12
38 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10.55 MED12
39 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.55 MED12
40 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.55 TP53
41 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.55 TP53
42 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.55 EGFR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.55 CTNNB1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.55 PIK3CA
45 Increased shRNA abundance (Z-score > 2) GR00366-A-62 10.55 TP53
46 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.55 KRAS
47 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.55 MED12
48 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.55 EGFR U2AF1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-89 10.55 MED12 U2AF1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.55 MED12

MGI Mouse Phenotypes related to Pancreatic Adenocarcinoma:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.5 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
2 homeostasis/metabolism MP:0005376 10.48 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
3 growth/size/body region MP:0005378 10.46 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
4 nervous system MP:0003631 10.42 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
5 normal MP:0002873 10.4 CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
6 muscle MP:0005369 10.38 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
7 cardiovascular system MP:0005385 10.38 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
8 digestive/alimentary MP:0005381 10.37 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
9 endocrine/exocrine gland MP:0005379 10.33 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
10 embryo MP:0005380 10.31 CDKN2A CTNNB1 EGFR ERBB2 GNAS KRAS
11 cellular MP:0005384 10.31 CDKN2A CTNNB1 EGFR ERBB2 GNAS KRAS
12 craniofacial MP:0005382 10.29 CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
13 limbs/digits/tail MP:0005371 10.28 CTNNB1 EGFR ERBB2 GNAS KRAS MED12
14 no phenotypic analysis MP:0003012 10.27 CDKN2A CTNNB1 EGFR GNAS HRAS KRAS
15 behavior/neurological MP:0005386 10.27 CDKN2A CTNNB1 ERBB2 GNAS HRAS KRAS
16 renal/urinary system MP:0005367 10.26 CTNNB1 EGFR GNAS HRAS KRAS MYCN
17 immune system MP:0005387 10.25 CDKN2A CTNNB1 EGFR GNAS KRAS LRRC56
18 liver/biliary system MP:0005370 10.24 CDKN2A CTNNB1 EGFR GNAS KRAS MYCN
19 pigmentation MP:0001186 10.18 CDKN2A CTNNB1 EGFR KRAS RXRA TP53
20 respiratory system MP:0005388 10.18 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
21 hearing/vestibular/ear MP:0005377 10.17 CTNNB1 EGFR GNAS KRAS MAP2K2 RXRA
22 skeleton MP:0005390 10.17 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
23 reproductive system MP:0005389 10.15 CDKN2A CTNNB1 EGFR ERBB2 KRAS LRRC56
24 vision/eye MP:0005391 10 CDKN2A CTNNB1 EGFR GNAS KRAS MAP2K2
25 hematopoietic system MP:0005397 9.93 CDKN2A CTNNB1 EGFR ERBB2 GNAS KRAS
26 mortality/aging MP:0010768 9.91 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
27 integument MP:0010771 9.5 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS

Drugs & Therapeutics for Pancreatic Adenocarcinoma

Drugs for Pancreatic Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 330)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
2
Desflurane Approved Phase 4 57041-67-5 42113
3 Anesthetics, Inhalation Phase 4
4 Anesthetics, General Phase 4
5
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2
6
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
7
Epirubicin Approved Phase 2, Phase 3 56420-45-2 41867
8
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
9
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
10
Phenytoin Approved, Vet_approved Phase 3 57-41-0 1775
11
Methoxsalen Approved Phase 3 298-81-7 4114
12
Olaparib Approved Phase 3 763113-22-0 23725625
13
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
14
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
15
Irofulven Investigational Phase 3 158440-71-2 3844471 148189
16 Chrysarobin Phase 2, Phase 3
17 Hematinics Phase 3
18 ON 01910 Phase 3
19 Formyltetrahydrofolates Phase 3
20 Tetrahydrofolates Phase 3
21 Antimitotic Agents Phase 3
22 Tubulin Modulators Phase 3
23 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
24 topoisomerase I inhibitors Phase 3
25 Calcium, Dietary Phase 3
26 Pharmaceutical Solutions Phase 3
27 Endothelial Growth Factors Phase 3
28 Immunoglobulins Phase 3
29 Antibodies, Monoclonal Phase 3
30 Antibodies Phase 3
31
Calcium Nutraceutical Phase 3 7440-70-2 271
32
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
33
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
34
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
35
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
37
Trastuzumab Approved, Investigational Phase 2 180288-69-1
38
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
39
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
40
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
41
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
42
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
43
Heparin, bovine Approved, Investigational, Withdrawn Phase 2 9005-49-6 22833565 9812414 772
44
Reviparin Approved, Investigational Phase 2 9041-08-1
45
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1
46
Dipyridamole Approved Phase 2 58-32-2 3108
47
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
48
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
49
Cobalt Approved, Experimental, Withdrawn Phase 2 7440-48-4 104729
50
Aldesleukin Approved Phase 1, Phase 2 110942-02-4

Interventional clinical trials:

(show top 50) (show all 741)
# Name Status NCT ID Phase Drugs
1 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
2 A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
3 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
4 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
5 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn NCT03891979 Phase 4 Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
6 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
7 Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Unknown status NCT02072616 Phase 3
8 Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
9 A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH) Unknown status NCT01077427 Phase 3 Gemcitabine + Capecitabine
10 A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen Unknown status NCT00088660 Phase 3
11 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
12 Phase II/III of Randomized Controlled Clinical Research on Irreversible Electroporation Synchronous Chemotherapy for Locally Advanced Pancreatic Adenocarcinoma Completed NCT03673137 Phase 2, Phase 3 Gemcitabine
13 A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma Completed NCT01964430 Phase 3 nab-Paclitaxel;Gemcitabine
14 Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma Completed NCT00033735 Phase 3 fluorouracil;Irofulven
15 A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine Completed NCT00099294 Phase 3 Glufosfamide
16 Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil Completed NCT00960284 Phase 2, Phase 3 capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
17 A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma Completed NCT03665441 Phase 3 eryaspase;Gemcitabine plus Abraxane;Irinotecan plus 5-FU plus leucovorin
18 A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02436668 Phase 3 Ibrutinib;Gemcitabine;Nab-paclitaxel
19 A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma Completed NCT00003216 Phase 3 fluorouracil;gemcitabine hydrochloride
20 Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma Completed NCT01526135 Phase 3 mFolfirinox;Gemcitabine
21 A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed NCT01746979 Phase 3 TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W)
22 A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment Completed NCT03126435 Phase 3 EndoTAG-1;Gemcitabine
23 A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT03943667 Phase 3 Gemcitabine;Paclitaxel
24 A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine
25 A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer Completed NCT00088894 Phase 3 gemcitabine hydrochloride
26 A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3 Albumin-bound paclitaxel (ABI-007);Gemcitabine
27 Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study Completed NCT00634725 Phase 3 capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
28 Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4) Completed NCT00044031 Phase 3
29 A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas Completed NCT03504423 Phase 3 CPI 613, mFolfirinox;Folfirinox
30 A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine Recruiting NCT01954992 Phase 3 Glufosfamide;Fluorouracil
31 A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma Recruiting NCT03899636 Phase 3 Modified FOLFIRINOX Regimen
32 Randomized Phase 3 Trial Comparing FOLFOX to Gemcitabine in Metastatic First-line in Patients With Pancreatic Adenocarcinoma and Non-fit for FOLFIRINOX Recruiting NCT04167007 Phase 3 Gemcitabine;FOLFOX
33 Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma Recruiting NCT03377491 Phase 3 Gemcitabine;nab paclitaxel
34 A Phase Ⅲ, Randomized Controlled Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine Versus mFOLFIRINOX in Treating Patients With Borderline Reseactable and Locally Advanced Pancreatic Cancer Recruiting NCT04617821 Phase 3 Nab paclitaxel plus gemcitabine;mFOLFIRINOX
35 A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer Recruiting NCT04340141 Phase 3 Oxaliplatin;Irinotecan Hydrochloride;Leucovorin Calcium;Fluorouracil
36 Precision Promise Platform Trial for Metastatic Pancreatic Cancer Recruiting NCT04229004 Phase 3 Gemcitabine combined with nab-paclitaxel;Dose -mFOLFIRINOX;Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel;Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine;Drug: Dose -SM-88
37 Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study Recruiting NCT04927780 Phase 3 Leucovorin Calcium;Fluorouracil;Irinotecan Hydrochloride;Oxaliplatin
38 Neoadjuvant Chemotherapy for Pancreatic Cancer; GS vs. GnP Recruiting NCT05268692 Phase 2, Phase 3 GS;GnP
39 Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors Recruiting NCT05181605 Phase 2, Phase 3 Folfirinox and Stereotactic Body Radiotherapy
40 Intrabdominal Hyperthermic Chemotherapy Using Gemcitabine to Treat Pancreatic Carcinomatosis Recruiting NCT03251365 Phase 2, Phase 3 HIPEC-gemcitabine
41 An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas Active, not recruiting NCT04083235 Phase 3 Irinotecan Liposomal Injection;Oxaliplatin;5Fluorouracil;Leucovorin;Nab-paclitaxel;Gemcitabine
42 A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy Active, not recruiting NCT02184195 Phase 3 Olaparib;Placebo
43 A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma Active, not recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
44 A Phase III, Multicenter, Prospective, Randomized, Patients With Resectable Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. Not yet recruiting NCT04835064 Phase 3 Nab paclitaxel;Gemcitabine;mFOLFIRINOX
45 Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease Not yet recruiting NCT05482516 Phase 3 Atezolizumab;Bevacizumab
46 Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma Terminated NCT01900327 Phase 3 Gemcitabine neoadjuvant;Gemcitabine adjuvant
47 An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1) Terminated NCT01956812 Phase 3 IMMU-107;placebo;Gemcitabine
48 Neoadjuvant Radiotherapy in Patients With Primary Resectable Adenocarcinoma of the Pancreatic Head Plus Adjuvant Chemotherapy: a Randomized Controlled Phase III Trial Terminated NCT01419002 Phase 3
49 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas Terminated NCT01231347 Phase 3 AMG 479;Placebo;gemcitabine
50 A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study) Terminated NCT02119663 Phase 3 Ruxolitinib;Placebo;Capecitabine

Search NIH Clinical Center for Pancreatic Adenocarcinoma

Genetic Tests for Pancreatic Adenocarcinoma

Genetic tests related to Pancreatic Adenocarcinoma:

# Genetic test Affiliating Genes
1 Pancreatic Adenocarcinoma 28

Anatomical Context for Pancreatic Adenocarcinoma

Organs/tissues related to Pancreatic Adenocarcinoma:

MalaCards : Pancreas, T Cells, Lymph Node, Endothelial, Lung, Liver, Colon

Publications for Pancreatic Adenocarcinoma

Articles related to Pancreatic Adenocarcinoma:

(show top 50) (show all 9752)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. 62
35898840 2023
3
Distal cholangiocarcinoma: case report and brief review of the literature. 62
36444360 2023
4
Anti‑silencing function 1B promotes the progression of pancreatic cancer by activating c‑Myc. 62
36416310 2023
5
Association of Textbook Outcome and Surgical Case Volume with Long-Term Survival in Patients Undergoing Surgical Resection for Pancreatic Cancer. 62
36102533 2022
6
Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. 62
36460898 2022
7
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. 62
35834777 2022
8
Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review. 62
36089524 2022
9
YAP activates pancreatic stellate cells and enhances pancreatic fibrosis. 62
35753954 2022
10
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma. 62
36056133 2022
11
Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma. 62
36102377 2022
12
Screening of an annexin-A2-targeted heptapeptide for pancreatic adenocarcinoma localization. 62
36453020 2022
13
Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. 62
36394449 2022
14
X-linked inhibitor of apoptosis protein is a prognostic marker for a favorable outcome in three identified subsets in resectable adenocarcinoma of the pancreas. 62
36472768 2022
15
Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma? 62
36094690 2022
16
Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review. 62
36084842 2022
17
Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma. 62
35362216 2022
18
Role of biliary drainage before pancreatoduodenectomy for pancreatic adenocarcinoma: a retrospective study. 62
35230040 2022
19
Radiofrequency Hyperthermia Enhances Locally Delivered Oncolytic Immuno-Virotherapy for Pancreatic Adenocarcinoma. 62
35902397 2022
20
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. 62
36463226 2022
21
Systematic analysis of expression profiles and prognostic significance of the FGF gene family in pancreatic adenocarcinoma. 62
36311692 2022
22
Role of Up-Regulated Transmembrane Channel-Like Protein 5 in Pancreatic Adenocarcinoma. 62
36459296 2022
23
Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD). 62
36328194 2022
24
NDUFA4 promotes cell proliferation by enhancing oxidative phosphorylation in pancreatic adenocarcinoma. 62
36307669 2022
25
Feasibility and outcome of spleen and vessel preserving total pancreatectomy (SVPTP) in pancreatic malignancies - a retrospective cohort study. 62
36169725 2022
26
Characterizing gastrointestinal dysfunction after pancreatic resection: a single-center retrospective study. 62
36435757 2022
27
High-risk liver patients are not associated with adverse events following pancreaticoduodenectomy. 62
36428108 2022
28
Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers. 62
36451048 2022
29
Assessment of spatial transcriptomics for oncology discovery. 62
36452860 2022
30
A pan-cancer analysis of the oncogenic role of ATP binding cassette subfamily E member 1 (ABCE1) in human tumors: An observational study. 62
36401432 2022
31
Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature. 62
35831529 2022
32
Evaluating the Impact of Preoperative Geriatric-Specific Variables and Modified Frailty Index on Postoperative Outcomes After Elective Pancreatic Surgery. 62
36076089 2022
33
Upregulation of dual-specificity phosphatase-26 is required for transforming growth factor β1(TGFβ1)-induced Epithelial-mesenchymal transition in A549 and PANC1 cells. 62
36053282 2022
34
Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies. 62
36402613 2022
35
Systematic review, meta-analysis and single-centre experience of the diagnostic accuracy of intraoperative near-infrared indocyanine green-fluorescence in detecting pancreatic tumours. 62
35654671 2022
36
Intramedullary pancreatic adenocarcinoma metastasis: The first case in literature. 62
36333089 2022
37
A Novel Immune-Related Gene Prognostic Index (IRGPI) in Pancreatic Adenocarcinoma (PAAD) and Its Implications in the Tumor Microenvironment. 62
36428747 2022
38
Oncological management dilemma: a rare presentation of hairy cell leukaemia with hepatic involvement presenting concomitantly with pancreatic adenocarcinoma. 62
36414341 2022
39
Identification of a novel cell cycle-related risk signature predicting prognosis in patients with pancreatic adenocarcinoma. 62
36401386 2022
40
Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. 62
36048239 2022
41
A novel risk score model based on four angiogenesis long non-coding RNAs for prognosis evaluation of pancreatic adenocarcinoma. 62
36384673 2022
42
Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART). 62
36420193 2022
43
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma. 62
36427115 2022
44
LRRC8A Is a Promising Prognostic Biomarker and Therapeutic Target for Pancreatic Adenocarcinoma. 62
36428619 2022
45
Molecular subtyping based on TRP family and prognostic assessment for TRP-associated lncRNAs in pancreatic adenocarcinoma. 62
36371178 2022
46
Prolonged complete response after neoadjuvant capecitabine-gemcitabine for a locally advanced pancreatic adenocarcinoma: A case report. 62
36412306 2022
47
Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. 62
36114896 2022
48
Clinicopathological features, prognostic significance, and associated tumor cell functions of family with sequence similarity 111 member B in pancreatic adenocarcinoma. 62
36408702 2022
49
KLF16 promotes pancreatic adenocarcinoma cell proliferation and migration by positively regulating SMAD6. 62
36438710 2022
50
Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort. 62
36358831 2022

Variations for Pancreatic Adenocarcinoma

ClinVar genetic disease variations for Pancreatic Adenocarcinoma:

5 (show top 50) (show all 668)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 POLE NM_006231.4(POLE):c.857C>A (p.Pro286His) SNV Likely Pathogenic
376502 rs1057519943 GRCh37: 12:133253184-133253184
GRCh38: 12:132676598-132676598
2 POLE NM_006231.4(POLE):c.856C>T (p.Pro286Ser) SNV Likely Pathogenic
376501 rs1057519944 GRCh37: 12:133253185-133253185
GRCh38: 12:132676599-132676599
3 RXRA NM_002957.6(RXRA):c.1280C>A (p.Ser427Tyr) SNV Likely Pathogenic
376529 rs1057519958 GRCh37: 9:137328351-137328351
GRCh38: 9:134436505-134436505
4 RXRA NM_002957.6(RXRA):c.1280C>T (p.Ser427Phe) SNV Likely Pathogenic
376528 rs1057519958 GRCh37: 9:137328351-137328351
GRCh38: 9:134436505-134436505
5 U2AF1 NM_006758.3(U2AF1):c.101C>T (p.Ser34Phe) SNV Likely Pathogenic
376025 rs371769427 GRCh37: 21:44524456-44524456
GRCh38: 21:43104346-43104346
6 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr) SNV Likely Pathogenic
376486 rs1057519937 GRCh37: 3:178952073-178952073
GRCh38: 3:179234285-179234285
7 HRAS, LRRC56 NM_005343.4(HRAS):c.182A>C (p.Gln61Pro) SNV Likely Pathogenic
376322 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
8 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu) SNV Likely Pathogenic
376487 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
9 HRAS, LRRC56 NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Likely Pathogenic
180848 rs104894226 GRCh37: 11:534285-534285
GRCh38: 11:534285-534285
10 CTNNB1 NM_001904.4(CTNNB1):c.121A>G (p.Thr41Ala) SNV Likely Pathogenic
17580 rs121913412 GRCh37: 3:41266124-41266124
GRCh38: 3:41224633-41224633
11 HRAS, LRRC56 NM_005343.4(HRAS):c.181C>G (p.Gln61Glu) SNV Likely Pathogenic
376444 rs28933406 GRCh37: 11:533875-533875
GRCh38: 11:533875-533875
12 PIK3CA NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val) SNV Likely Pathogenic
376485 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
13 MAP2K2 NM_030662.4(MAP2K2):c.169T>G (p.Phe57Val) SNV Likely Pathogenic
8273 rs121434498 GRCh37: 19:4117551-4117551
GRCh38: 19:4117553-4117553
14 CDKN2A NM_000077.5(CDKN2A):c.247C>G (p.His83Asp) SNV Likely Pathogenic
376380 rs121913385 GRCh37: 9:21971111-21971111
GRCh38: 9:21971112-21971112
15 HRAS, LRRC56 NM_005343.4(HRAS):c.38G>C (p.Gly13Ala) SNV Likely Pathogenic
376443 rs104894226 GRCh37: 11:534285-534285
GRCh38: 11:534285-534285
16 HRAS, LRRC56 NM_005343.4(HRAS):c.182A>T (p.Gln61Leu) SNV Likely Pathogenic
376033 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
17 MAP2K2 NM_030662.4(MAP2K2):c.171T>G (p.Phe57Leu) SNV Likely Pathogenic
376449 rs1057519910 GRCh37: 19:4117549-4117549
GRCh38: 19:4117551-4117551
18 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely Pathogenic
13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
19 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely Pathogenic
13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
20 MED12 NM_005120.3(MED12):c.3670C>G (p.Leu1224Val) SNV Likely Pathogenic
376452 rs1057519912 GRCh37: X:70349258-70349258
GRCh38: X:71129408-71129408
21 CTNNB1 NM_001904.4(CTNNB1):c.122C>A (p.Thr41Asn) SNV Likely Pathogenic
376394 rs121913413 GRCh37: 3:41266125-41266125
GRCh38: 3:41224634-41224634
22 U2AF1 NM_006758.3(U2AF1):c.101C>A (p.Ser34Tyr) SNV Likely Pathogenic
376026 rs371769427 GRCh37: 21:44524456-44524456
GRCh38: 21:43104346-43104346
23 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely Pathogenic
375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
24 CDKN2A NM_000077.5(CDKN2A):c.150G>T (p.Gln50His) SNV Likely Pathogenic
376384 rs1057519882 GRCh37: 9:21974677-21974677
GRCh38: 9:21974678-21974678
25 ERBB2 NM_004448.4(ERBB2):c.2524G>A (p.Val842Ile) SNV Likely Pathogenic
375994 rs1057519738 GRCh37: 17:37881332-37881332
GRCh38: 17:39725079-39725079
26 KRAS NM_004985.5(KRAS):c.183A>T (p.Gln61His) SNV Likely Pathogenic
45117 rs17851045 GRCh37: 12:25380275-25380275
GRCh38: 12:25227341-25227341
27 MED12 NM_005120.3(MED12):c.3670C>T (p.Leu1224Phe) SNV Likely Pathogenic
376451 rs1057519912 GRCh37: X:70349258-70349258
GRCh38: X:71129408-71129408
28 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) SNV Likely Pathogenic
13653 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
29 CTNNB1 NM_001904.4(CTNNB1):c.97T>A (p.Ser33Thr) SNV Likely Pathogenic
376393 rs1057519886 GRCh37: 3:41266100-41266100
GRCh38: 3:41224609-41224609
30 CTNNB1 NM_001904.4(CTNNB1):c.98C>T (p.Ser33Phe) SNV Likely Pathogenic
17583 rs121913400 GRCh37: 3:41266101-41266101
GRCh38: 3:41224610-41224610
31 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely Pathogenic
217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
32 CTNNB1 NM_001904.4(CTNNB1):c.98C>A (p.Ser33Tyr) SNV Likely Pathogenic
17577 rs121913400 GRCh37: 3:41266101-41266101
GRCh38: 3:41224610-41224610
33 SF3B2 NM_006842.3(SF3B2):c.2099A>G (p.Glu700Gly) SNV Likely Pathogenic
376533 rs1057519960 GRCh37: 11:65830884-65830884
GRCh38: 11:66063413-66063413
34 CTNNB1 NM_001904.4(CTNNB1):c.98C>G (p.Ser33Cys) SNV Likely Pathogenic
376231 rs121913400 GRCh37: 3:41266101-41266101
GRCh38: 3:41224610-41224610
35 MYCNOS, MYCN NM_005378.6(MYCN):c.131C>T (p.Pro44Leu) SNV Likely Pathogenic
376460 rs1057519919 GRCh37: 2:16082317-16082317
GRCh38: 2:15942195-15942195
36 PIK3CA NM_006218.4(PIK3CA):c.3141T>G (p.His1047Gln) SNV Likely Pathogenic
376481 rs1057519932 GRCh37: 3:178952086-178952086
GRCh38: 3:179234298-179234298
37 CTNNB1 NM_001904.4(CTNNB1):c.97T>G (p.Ser33Ala) SNV Likely Pathogenic
376392 rs1057519886 GRCh37: 3:41266100-41266100
GRCh38: 3:41224609-41224609
38 CTNNB1 NM_001904.4(CTNNB1):c.97T>C (p.Ser33Pro) SNV Likely Pathogenic
376391 rs1057519886 GRCh37: 3:41266100-41266100
GRCh38: 3:41224609-41224609
39 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely Pathogenic
13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
40 PIK3CA NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp) SNV Likely Pathogenic
156446 rs587777790 GRCh37: 3:178917478-178917478
GRCh38: 3:179199690-179199690
41 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Likely Pathogenic
39705 rs121913281 GRCh37: 3:178952084-178952084
GRCh38: 3:179234296-179234296
42 PIK3CA NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile) SNV Likely Pathogenic
179173 rs121913283 GRCh37: 3:178952074-178952074
GRCh38: 3:179234286-179234286
43 TP53 NM_000546.6(TP53):c.518T>G (p.Val173Gly) SNV Likely Pathogenic
376016 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
44 TP53 NM_000546.6(TP53):c.706T>G (p.Tyr236Asp) SNV Likely Pathogenic
142183 rs587782289 GRCh37: 17:7577575-7577575
GRCh38: 17:7674257-7674257
45 TP53 NM_000546.6(TP53):c.452C>G (p.Pro151Arg) SNV Likely Pathogenic
376640 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160
46 TP53 NM_000546.6(TP53):c.613T>G (p.Tyr205Asp) SNV Likely Pathogenic
376686 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
47 TP53 NM_000546.6(TP53):c.452C>A (p.Pro151His) SNV Likely Pathogenic
376639 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160
48 TP53 NM_000546.6(TP53):c.577C>A (p.His193Asn) SNV Likely Pathogenic
376614 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
49 TP53 NM_000546.6(TP53):c.824G>T (p.Cys275Phe) SNV Likely Pathogenic
376582 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
50 TP53 NM_000546.6(TP53):c.644G>A (p.Ser215Asn) SNV Likely Pathogenic
376662 rs587782177 GRCh37: 17:7578205-7578205
GRCh38: 17:7674887-7674887

Expression for Pancreatic Adenocarcinoma

Search GEO for disease gene expression data for Pancreatic Adenocarcinoma.

Pathways for Pancreatic Adenocarcinoma

Pathways related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
2
Show member pathways
13.87 TP53 SMAD4 PIK3CA MUC4 MAP2K2 KRAS
3 13.82 CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
4
Show member pathways
13.78 CDKN2A EGFR ERBB2 GNAS HRAS KRAS
5
Show member pathways
13.78 CTNNB1 EGFR ERBB2 HRAS KRAS MAP2K2
6
Show member pathways
13.71 EGFR ERBB2 GNAS HRAS KRAS MAP2K2
7
Show member pathways
13.64 SMAD4 MAP2K2 KRAS HRAS GNAS ERBB2
8
Show member pathways
13.62 TP53 SMAD4 PIK3CA MAP2K2 KRAS HRAS
9
Show member pathways
13.55 TP53 PIK3CA MAP2K2 KRAS HRAS GNAS
10
Show member pathways
13.48 CTNNB1 EGFR GNAS HRAS KRAS MAP2K2
11
Show member pathways
13.47 CTNNB1 EGFR ERBB2 HRAS KRAS MAP2K2
12
Show member pathways
13.36 CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
13
Show member pathways
13.15 EGFR GNAS HRAS KRAS MAP2K2 TP53
14
Show member pathways
13.04 TP53 PIK3CA MAP2K2 KRAS HRAS EGFR
15
Show member pathways
13.01 TP53 PIK3CA MAP2K2 HRAS EGFR CDKN2A
16
Show member pathways
12.98 PIK3CA MAP2K2 KRAS HRAS GNAS CTNNB1
17
Show member pathways
12.96 PIK3CA MAP2K2 KRAS HRAS GNAS ERBB2
18
Show member pathways
12.94 TP53 SMAD4 PIK3CA MAP2K2 KRAS HRAS
19
Show member pathways
12.92 PIK3CA MAP2K2 KRAS HRAS EGFR
20
Show member pathways
12.91 PIK3CA MAP2K2 KRAS HRAS CTNNB1
21 12.91 PIK3CA MYCN MAP2K2 KRAS HRAS ERBB2
22
Show member pathways
12.87 TP53 MAP2K2 KRAS HRAS GNAS CTNNB1
23
Show member pathways
12.85 SMAD4 KRAS HRAS EGFR CTNNB1
24
Show member pathways
12.77 MAP2K2 KRAS HRAS GNAS EGFR
25
Show member pathways
12.77 MAP2K2 KRAS HRAS GNAS EGFR CTNNB1
26
Show member pathways
12.76 TP53 MAP2K2 KRAS HRAS EGFR
27
Show member pathways
12.76 MAP2K2 KRAS HRAS GNAS EGFR CDKN2A
28 12.76 TP53 PIK3CA MAP2K2 HRAS EGFR CTNNB1
29
Show member pathways
12.73 TP53 PIK3CA MAP2K2 KRAS HRAS EGFR
30
Show member pathways
12.67 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
31
Show member pathways
12.56 TP53 PIK3CA MAP2K2 HRAS ERBB2 CTNNB1
32
Show member pathways
12.54 EGFR HRAS KRAS MAP2K2 PIK3CA
33
Show member pathways
12.52 CTNNB1 EGFR ERBB2 HRAS KRAS MAP2K2
34
Show member pathways
12.52 TP53 SMAD4 RXRA PIK3CA MAP2K2 KRAS
35
Show member pathways
12.51 PIK3CA MAP2K2 KRAS HRAS EGFR
36 12.5 TP53 MAP2K2 KRAS HRAS EGFR
37
Show member pathways
12.5 PIK3CA MAP2K2 KRAS HRAS CTNNB1
38
Show member pathways
12.49 PIK3CA MAP2K2 KRAS HRAS
39
Show member pathways
12.49 TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
40
Show member pathways
12.47 PIK3CA MAP2K2 KRAS HRAS ERBB2 EGFR
41
Show member pathways
12.42 TP53 PIK3CA MAP2K2 HRAS GNAS
42
Show member pathways
12.41 PIK3CA MAP2K2 HRAS CTNNB1
43
Show member pathways
12.41 CTNNB1 EGFR ERBB2 HRAS KRAS MAP2K2
44
Show member pathways
12.4 PIK3CA MAP2K2 KRAS HRAS
45
Show member pathways
12.4 PIK3CA KRAS HRAS CTNNB1
46 12.4 PIK3CA HRAS ERBB2 EGFR CTNNB1
47
Show member pathways
12.39 RXRA PIK3CA MAP2K2 HRAS GNAS ERBB2
48
Show member pathways
12.35 TP53 PIK3CA MAP2K2 HRAS
49 12.35 PIK3CA MAP2K2 KRAS HRAS EGFR
50
Show member pathways
12.35 EGFR ERBB2 HRAS KRAS PIK3CA

GO Terms for Pancreatic Adenocarcinoma

Cellular components related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.44 PIK3CA MAP2K2 HRAS GNAS ERBB2 EGFR

Biological processes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.39 CDKN2A CTNNB1 EGFR HRAS MED12 MYCN
2 positive regulation of DNA-templated transcription GO:0045893 10.25 TP53 SMAD4 RXRA MYCN MED12 MAP2K2
3 negative regulation of gene expression GO:0010629 10.18 TP53 PIK3CA MYCN HRAS CTNNB1
4 heart development GO:0007507 10.08 TP53 MED12 MAP2K2 ERBB2 CTNNB1
5 MAPK cascade GO:0000165 10.07 CTNNB1 EGFR HRAS KRAS MAP2K2
6 Ras protein signal transduction GO:0007265 10.01 TP53 KRAS HRAS CDKN2A
7 positive regulation of gene expression GO:0010628 9.93 TP53 MYCN MAP2K2 KRAS HRAS ERBB2
8 cell population proliferation GO:0008283 9.91 TP53 SMAD4 KRAS EGFR CTNNB1
9 embryonic organ development GO:0048568 9.73 CTNNB1 MED12 POLE TP53
10 negative regulation of immature T cell proliferation in thymus GO:0033088 9.69 ERBB2 CDKN2A
11 hair follicle placode formation GO:0060789 9.67 GNAS CTNNB1
12 regulation of cell population proliferation GO:0042127 9.5 TP53 SMAD4 HRAS ERBB2 EGFR CTNNB1
13 positive regulation of miRNA maturation GO:1903800 9.02 TP53 MYCN MAP2K2 EGFR

Molecular functions related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 10.1 TP53 SMAD4 POLE MED12 EGFR CTNNB1
2 nucleotide binding GO:0000166 9.91 POLE PIK3CA MAP2K2 KRAS HRAS GNAS
3 protein phosphatase binding GO:0019903 9.56 TP53 ERBB2 EGFR CTNNB1
4 disordered domain specific binding GO:0097718 9.55 TP53 CTNNB1 CDKN2A
5 protein serine/threonine kinase activator activity GO:0043539 9.02 PIK3CA MAP2K2 KRAS HRAS

Sources for Pancreatic Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....